{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:27:46Z","timestamp":1768004866008,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Diagnostic challenges combined with the vulnerability of neonates to develop invasive candidiasis (IC) may lead to antifungal administration in the absence of IC. A modified point-prevalence study was performed to obtain an improved insight and understanding of antifungal prescribing in this specific patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Neonates and infants \u226490 days of age receiving systemic antifungals from 12 centers in England were included. Data were collected prospectively during 26 consecutive weeks and entered into an online REDCap database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two hundred eighty neonates and infants were included, the majority \u22641 month of age (68.2%). Prematurity was the commonest underlying condition (68.9%). Antifungals were prescribed for prophylactic reason in 79.6%; of those, 64.6% and 76.3% were extreme low birth weight infants and prematurely born neonates, respectively. Additional risk factors were present in almost all patients, but only 44.7% had \u22653 risk factors rendering them more susceptible to develop IC. Nonpremature and non extremely low birth weight premature infants only scored \u22653 risk factors in 32.6% and 15%, respectively. Fluconazole was the most common antifungal used (76.7% of all prescriptions), and commonly underdosed as treatment. The number of microbiologic proven IC was low, 5.4%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Neonatal antifungal prophylaxis is commonly prescribed outside the recommendations based on known risk profiles. Fluconazole is the main antifungal prescribed in neonates and infants, with underdosing frequently observed when prescribed for treatment. Number of proven IC was very low. These observations should be taken into consideration to develop a national pediatric Antifungal Stewardship program aiming to guide rational prescribing.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002463","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T08:44:56Z","timestamp":1569487496000},"page":"1219-1223","source":"Crossref","is-referenced-by-count":19,"title":["Neonatal Antifungal Consumption Is Dominated by Prophylactic Use; Outcomes From The Pediatric Antifungal Stewardship: Optimizing Antifungal Prescription Study"],"prefix":"10.1097","volume":"38","author":[{"given":"Laura","family":"Ferreras-Antol\u00edn","sequence":"first","affiliation":[{"name":"Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, Aberdeen"},{"name":"St George\u2019s University Hospitals NHS Foundation Trust"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom"},{"name":"The University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayad","family":"Atra","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology, Royal Marsden Hospital, Downs Road, Sutton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Dermirjian","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, Evelina Children Hospital, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Emonts","sequence":"additional","affiliation":[{"name":"Department of Paediatric Immunology, Infectious Diseases and Allergy, Great North Children\u2019s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust"},{"name":"Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paddy","family":"McMaster","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Royal Manchester Childrens\u00b4 Hospital, Manchester"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Paulus","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford"},{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, University Hospital Southampton NHS Foundation Trust, Southampton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Kinsey","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology and Oncology, Leeds General Infirmary, Leeds"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Vergnano","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Bristol Royal Hospital for Children, Bristol"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Whittaker","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, Aberdeen"},{"name":"Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240429","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of invasive fungal disease in children.","volume":"6","author":"Pana","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"suppl 1","key":"R2-20240429","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S0163-4453(17)30200-1","article-title":"Recognition and diagnosis of invasive fungal infections in neonates.","volume":"74","author":"Calley","year":"2017","journal-title":"J Infect"},{"key":"R3-20240429","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-20240429","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0032-1329688","article-title":"Risk factors and clinical analysis for invasive fungal infection in neonatal intensive care unit patients.","volume":"30","author":"Yu","year":"2013","journal-title":"Am J Perinatol"},{"key":"R5-20240429","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.inf.0000168751.11375.d6","article-title":"Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000.","volume":"24","author":"Shetty","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20240429","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/INF.0b013e3182769603","article-title":"Risk factors for invasive candidiasis in infants >1500\u2009g birth weight.","volume":"32","author":"Lee","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20240429","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1136\/adc.2005.082024","article-title":"Invasive fungal infection in very low birthweight infants: national prospective surveillance study.","volume":"91","author":"Clerihew","year":"2006","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R8-20240429","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 7","key":"R9-20240429","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R10-20240429","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12281-017-0274-9","article-title":"Progress in the diagnosis of invasive fungal disease in children.","volume":"11","author":"Warris","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"key":"R11-20240429","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/14787210.2015.1028366","article-title":"Impact of special patient populations on the pharmacokinetics of echinocandins.","volume":"13","author":"Muilwijk","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R12-20240429","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2017-1849","article-title":"Pediatric antibacterial and antifungal trials From 2007 to 2017.","volume":"142","author":"Thaden","year":"2018","journal-title":"Pediatrics"},{"key":"R13-20240429","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.coph.2015.08.009","article-title":"Clinical pharmacology of antifungal agents in pediatrics: children are not small adults.","volume":"24","author":"Ramos-Mart\u00edn","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"R14-20240429","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/INF.0000000000001068","article-title":"Cost analysis of fluconazole prophylaxis for prevention of neonatal invasive candidiasis.","volume":"35","author":"Swanson","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20240429","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1510\/icvts.2010.257931","article-title":"Candidemia after cardiac surgery in the intensive care unit: an observational study.","volume":"12","author":"Pasero","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R16-20240429","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1097\/INF.0000000000000274","article-title":"Infections in patients admitted to pediatric intensive care units: development of ERICAP scoring system.","volume":"33","author":"Jordan","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20240429","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1542\/peds.2011-3620","article-title":"Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009.","volume":"130","author":"Chitnis","year":"2012","journal-title":"Pediatrics"},{"key":"R18-20240429","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.04109-14","article-title":"Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.","volume":"59","author":"Lestner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20240429","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/INF.0000000000002317","volume":"38","author":"Ferreras-Antolin","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20240429","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population pharmacokinetics of fluconazole in young infants.","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20240429","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/INF.0b013e3182467a72","article-title":"Antifungal therapy and outcomes in infants with invasive Candida infections.","volume":"31","author":"Ascher","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20240429","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/bcp.12025","article-title":"Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.","volume":"75","author":"Lestner","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20240429","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciw363","article-title":"Fluconazole prophylaxis for the prevention of candidiasis in premature infants: a meta-analysis using patient-level data.","volume":"63","author":"Ericson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R24-20240429","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/INF.0b013e318202cbb3","article-title":"Fluconazole loading dose pharmacokinetics and safety in infants.","volume":"30","author":"Piper","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20240429","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/INF.0b013e31819f1f50","article-title":"Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.","volume":"28","author":"Wade","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20240429","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/14787210.2016.1242413","article-title":"Expert review of anti-infective therapy diagnosis of invasive fungal diseases in pediatric patients diagnosis of invasive fungal diseases in pediatric patients.","volume":"7210","author":"Pana","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R27-20240429","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/jama.2014.2624","article-title":"Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.","volume":"311","author":"Benjamin","year":"2014","journal-title":"JAMA"},{"key":"R28-20240429","first-page":"788","article-title":"Fluconazole pharmacokinetics and safety in premature infants.","volume":"45","author":"Turner","year":"2012","journal-title":"Acc Chem Res"},{"key":"R30-20240429","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20240429","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/archdischild-2012-303350","article-title":"Update on the management of Candida infections in preterm neonates.","volume":"100","author":"Manzoni","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R32-20240429","first-page":"150","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.","volume":"28A","author":"Autmizguine","year":"2011","journal-title":"IUCN Otter Spec Gr Bull"},{"key":"R33-20240429","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jphp.12878","article-title":"Comprehensive drug utilization review in neonates: liposomal amphotericin B.","volume":"70","author":"Silver","year":"2018","journal-title":"J Pharm Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:12:21Z","timestamp":1714414341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002463","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}